In light of the current situation of elective surgery being postponed across the NHS, we aim to treat 500 NHS patients, at no charge, with the world’s leading viscosupplementation, Monovisc, or with the world’s only combination hyaluronic acid plus steroid, Cingal.
This is to assist the patients of our customers who have suffered cancellation of their surgery due to the COVID-19 crisis.
As an independent UK company, we stand behind and support the NHS and are privileged to work with it's clinical teams every day.
Monovisc is a 100% pure Hyaluronic Acid alternative that can be safely administered if the use of glucocorticoids is contraindicated in any way.
Combined with Monovisc, Cingal contains triamcinolone hexacetonide corticosteroid. Clinicians are advised to follow local NHS guidelines for the use of steroids during this time.
Triamcinolone hexacetonide in Cingal
The triamcinolone hexacetonide corticosteroid within Cingal acts as an anti-inflammatory to provide short-term pain relief when used as an intra-articular injection in osteoarthritic joints.
There is no specific recommendation related to the Coronavirus crisis we are experiencing, however caution should be used in the event of exposure to communicable diseases and for patients classified as “at risk”, since the course of specific viral diseases may be particularly severe in patients treated with glucocorticoids.
At particular risk are individuals with no history of chickenpox or measles infection. If such individuals should come into contact with chickenpox or measles sufferers during treatment with Triamcinolone hexacetonide, prophylactic treatment should be considered as appropriate.
An independent Research Fellow will follow up the results from this initiative. You can either download the form to fill in or use the online version below.